Plus Therapeutics (NASDAQ:CNSY) Releases Quarterly Earnings Results

Plus Therapeutics (NASDAQ:CNSY) announced its quarterly earnings results on Friday. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by ($0.35), Zacks reports. Plus Therapeutics had a negative return on equity of 198.48% and a negative net margin of 230.24%.

Plus Therapeutics Stock Performance

Shares of NASDAQ:CNSY traded down $0.02 during mid-day trading on Friday, reaching $3.68. 95,231 shares of the stock were exchanged, compared to its average volume of 306,130. The company has a market cap of $25.33 million, a PE ratio of -1.60 and a beta of 1.42. Plus Therapeutics has a one year low of $2.90 and a one year high of $23.42.

Analysts Set New Price Targets

CNSY has been the subject of several research analyst reports. Zacks Research lowered Plus Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, August 3rd. Weiss Ratings started coverage on shares of Plus Therapeutics in a research note on Tuesday, August 4th. They issued a “sell (e+)” rating on the stock. Two research analysts have rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

About Plus Therapeutics

Plus Therapeutics, Inc is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s technology is designed to deliver radioactive payloads directly to tumors, with the goal of improving local treatment while limiting exposure to surrounding healthy tissue.

Its lead investigational product is rhenium-186 nanoliposomes, also known as 186RNL, a nanotechnology-based radiotherapeutic being evaluated for recurrent glioblastoma and leptomeningeal metastases.